Keith Gottesdiener, M.D. is the chief executive officer of Rhythm Therapeutics, joining Rhythm after 16 years at Merck Research Laboratories. At Merck, Dr. Gottesdiener held positions of increasing responsibility, including leading Merck’s early clinical development across all therapeutic areas from 2001 through early 2006. From 2006-2011, he was a leader of Merck’s late clinical development organization, first overseeing the development of Merck’s infectious diseases and vaccine products through pivotal trials, registration, and lifecycle management. Dr. Gottesdiener led Merck’s late-stage clinical development efforts (from Phase 2 thru patent expiry) across all therapeutic areas beginning in 2008. Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania and completed his residency and fellowship at the Brigham and Women’s Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children’s Hospital programs. After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory of Dr. Jack Strominger at Dana Farber Cancer Institute working on the molecular immunology of the T-cell receptor.